I may be wrong, but I get the feeling you think FTO inhibitors...

I may be wrong, but I get the feeling you think FTO inhibitors are cardiotoxic. FTO inhibitors have only demonstrated measureable cardiotoxicity when used in combination with cardiotoxic drugs in vitro/vivo. I haven't found any evidence that demonstrates a significant increase in cardiotoxicity from a single agent FTO inhibitor/knockdown model. If the combination effects demonstrated in cell and animal models translates to additional cardiotoxicity in patients, it is bad for FTO inhibitors, but very good for us. I don't know how the FDA will handle a meaningful percentage increase in cancer therapy-related cardiac events from a new drug class.

Just going to sit here twiddling my thumbs until RAC announce the cardio MoA('s?). It must be very strong, as it has to overcome the synergy between FTO inhibition and DOX. Just imagine if it is regeneration...